Mind MedicineCA60255C8850MNMDMNMD
Financials
Market Cap
$590.79M5Y beta
-7.28EPS (TTM)
-$2.936Free Float
69.95MEBITDA (TTM)
-$92.28MFree Cashflow (TTM)
-$67.63MPricing
Analyst Ratings
The price target is $23.86 and the stock is covered by 8 analysts.
Buy
7
Hold
1
Sell
0
Information
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).